The role of radiotherapy in the treatment of malignant melanoma  by Skowronek, J. et al.
J. Skowronek et. al.: The role of radiotherapy....
ORIGINAL PAPER
THE ROLE OF RADIOTHERAPY IN THE TREATMENT OF MALIGNANT
MELANOMA.
J. Skowronek, M. Matecka-Nowak, E. Nowakowska, A. O'Shea, M. Kubaszewska
Department of Radiotherapy, GreatPoland Cancer Center, Poznań
Received 24 November 1997; revision received 9 March 1998; accepted 2 April 1998.
SUMMARY
Malignant Melanoma is recognised by several
radiotherapists to be radioresistanł. Many
radiobiological data and well-known differences in
the morphology of melanoma suggest that this
c1aim may be false.
Tt"le data obtained are presented in the paper in a
historical overview. Principles of the radiotherapy
of melanoma are discussed. The results of
palliative irradiation of 27 patients, treated at the
GreatPoland Cancer Center in the years 1985-
1989 are discussed.
HISTORY
Malignant melanoma has been for many years
recognised as a radioresistant tumour basing on a
limited number of observations, or lack of
regression observed in tumours after conventional
treatment (1,8 - 3,0 Gy per day). The rationale for
using irradiationtechnique has been questioned.
Special controversy has arisen over the dose per
fraction, overall dose and fractionation schedule.
Regardless of doubts and controversies,
melanoma was one of the first tumours irradiated
(Peschel, 1986; Trott, 1993).
Miescher was among the first authors who
printed to differences in the morphology of
melanoma and thus to a resulting difference in
radiosensivity. He observed higher remissions in
tumours that had a higher therapeutic ratio
(Miescher,1926). In 1931, Evans and Leucutia
described 30 patients treated successfully only
with radiotherapy (Evans, 1931). The
investigations by Ellis led to a large number of
valuable conlusions. He used atotal dose of 55 -
60 Gy for 7-10 days. Complete remission was
observed in 12 patients in a group of 38 irradiated
patients (Ellis, 1939).
Another author who suggested that melanoma
is not a radioresistant tumour is Hellriegel. He
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based his observations on an extensive study
made over 25 years (Hellriegel, 1963).
In a group of 95 patients treated only with
irradiation he achieved 68% 5-year free-survivals,
in the group of 105 patients with a more advanced
form of melanoma treated with surgery and
irradiation he achieved 62% of 5-year free-
survivals.
The daily dose used in the orthovoltage era was
1000 R whereas the total dose was 10000 R for
the energy of 30 kV - 50 kV. In the megavoltage
era, the most frequently used doses were 50 Gy
administered in 20 fractions. This treatment
brought in an increase in local and metastatic
regression in tumours (Trott, 1993).
Development in radiobiology- resulted in a charge
in the recognition of melanoma as a radioresistant
tumour.
RADIOBIOLOGICAL CONSIDERATIONS
In 1971 in two papers, similar results concerning
the radiobiology of melanoma cells were
presented. Barranco et al. published a report
which focused on melanoma radiosensivity
(Barranco, 1971). The authors proved that the celi
survival curve on the skin melanoma cells, shows
an atypical wide arm of radioresistency. The value
of this discovery was elear for radiobiologists and
radiotherapists. The "in vitro" research showed
that melanoma cells had a great ability to
sublethal damages repairmenł.
This provided explanation for the melanoma
radioresistency during conventional treatment
(Meder, 1985). Dewey published similar results
obtained from "in vitro" cells (Dewey, 1971). The
wide arm of radioresistency was observed when
low doses of irradiation were used. He suggested
that the use of doses per fraction greater than 4,2
Gy would be more appropriate.
Ellis when using the data obtained by Dewey
was able to ascertain the influence of the dose per
fraction on the probability of cure (NSD pattern)
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for tumours with different radioresistency arms on
the survival curves. He c1aimed that in the case of
a high extrapolation number (the ability for
sublethal damages repairment), the sterilization
effect for the same NSD (similar damages of
healthy cells) is larger for a smali number of high
fractions rather than that for a high number of low
fractions. The high extrapolation number is typical
for radioresistant tumours. Ellis suggested the use
of several high doses for such "radioresistant
tumours" (6 Gy or more). His recommendations
were accepted by several radiotherapstis who
often obtained high percentages of tumour local
controls.
Many researches has been done during the last
25 years with often contradictory results (Jenrette,
1996). Thus it was possible to verify Elliss's
observations.
Rofstad compared the parameters from the
survival curves obtained from melanoma celi lines
isolated from· xenografts and directly from
pathological sampies (Rofstad, 1986). He failed to
prove theinfluence of cells origin on the survival
curve parameters. In every group of cells he
observed a wide range of Do [dose gives an
average ofone hit per target] (0,57-2,11 Gy) and
extrapolation values(1-78). For his analysis he
used a linear-quadratic model and an alpha/beta
ratio. -
The average extrapolation number was 5, but
30% of the values were above 10 or below 3. The
average alphalbeta ratio was 7 Gy, 30% of the
values were below 3 Gy and 30% of them were
above 10 Gy. These results proved the
heterogeneity of melanoma cells.
Wideł presented the results based on human
xenografts characteristics (Wideł, 1996). She
showed the existence of differences in the
dimension of nonoxydatic cellS' vascularisation
density and reoxygenation level during
radiotherapy and also in the ability of sublethal
and repairment of lethal damages. These
differences can have an influence (apart from
radiosensivity) on the heterogeneous response to
fractionated radiotherapy. Clinical data showed
that the alpha/beta ratio for "in vitro" irradiated
cells for different 40 celi lines varied from 0,5 to
63,8 Gy. The radiotherapy of melanoma demands
an individualized selection of dosas per fraction.
Wideł suggests a potential usefulness of the study
of the "in vitro" melanoma cells radiosensivity for
individualisationof the procedure.
The recommended tests for radiosensivity are
the following:
- the indirect SF-2 test (survival fraction 2Gy)
- the mieronuclear test and
- the fibroblasts differentiation test.
The value of the radiobiological study is limited
by the ineomplete eomplementariness of the "in
vitro" and "in vivo" eells researeh. It is well known
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that a large number (6% to 85%) of cells are
hipoxie (Rofstad, 1990; Weisehelbaum, 1984).
Since the oxygenation of cells is one of the most
important factors in cells radiosensivity, it is
possible to achieve different results inthe same
Iines of cells in the "in vitro" and " in vivo "
conditions.
There are many other faetors influencing
melanoma cells radiosensivity such as celi
damage repairment, phases in the eellular cycle,
genetic dependent radiosensivity, hipoxie fraction,
ability for reoxygenation and repopulation. Ali
these factors may have a great influence on the
radiosensivity.
Weischelbaum et al. suggested that tumours
radioresisteney may depend on the ability to
sublethal damages repairment (UPL)
(Weischelbaum, 1984).
The discussion on the protoeol is still open. It
seems that the "dose - time ratio" and the various
values of the alpha/beta ratios can have an
important effect on the radiotherapy of melanoma
(especially on the changes in doses perfraetion)
(Wannenmacher, 1986).
PRINCIPLES OF MELANOMA RADIOTHERAPY
Since the 1970's , high doses have been used
in melanoma irradiation (4 - 9 Gy) once or twice a
week, with eomplete remissions and long - time
survivals (Adam, 1982; Habermalz, 1976;
Hornsey, 1978; Overgaard, 1980; Skowronek,
1997; Strauss, 1981). Surgery is still treatment of
choice, therefore, the data available are mainlyon
palliative irradiation. Patients qualifiedfor
radiotherapy have usually tumours in an
advaneed stage, very often with metastases, and
thus not eligible for a comparison with patients
who undergo surgery.
This makes it impossible to determinate optimal
doses per fraction and total doses for complete
remission. In almost all cases, groups of patients
are not numerous enough, the localisations of
original tumour and metastases are varied, the
period of observation is short due to a Iimited
survival length, and the eriteria of the response
are influenced by the palliation effeet rather than
by the curing effect.
Habermalz has summarized the results of
several studies researehes (Habermaiz, 1981). In
the whole group, 38% (85/221) of eomplete
remissions were obtained after the irradiation of
metastases to the skin, subcułaneous tissue and
Iymph nodes. The percentage of remissions was
dependent on the doses per fraetion, rather than
on the total dose. The differences in the results
were especially notieeable in patients with partiaI
remissions : 54% (59/110) in a group irradiated
with a dose per fraction lower than 4 Gy, and 83%
(92/111) with a dose perfraction higher than 4 Gy.
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Different locations of tumours ( the large ones
wete irradiated more often but with lower doses ),
different total doses (a large number of tumours
were irradiated with conventional radiation of 20 x
2,5 Gy with inadequate total dose) and short
periods of follow-up have some influence on these
results.
Overgaard et al. conducted a retrospective
research (Overgaard, 1986). They published
results of radiotherapy in 100 patients with
metastases to skin or Iymph nodes. Complete
remission was achieved in 49% cases of skin
metastases and in 43% cases of Iymph node
remissions in period of more than 5 years. The
complete remission was independent of the total
dose, and of the dose per fraction lower than 3 Gy
in 38 patients. In these patients, the total dose
was also lower when compared with the total
doses in the treatment of other cancers. The most
important conlusion from Overgaard's research is
the definition of melanoma radiosensivity.
Besides, patients who had achieved complete
remission had great probability of local control and
improvement in their overall survival.
According to Overgaard et al., radiotherapy canbe a treatment of choice in patients with
melanoma metastases to skin and Iymph nodes.
Betier results can be achieved using radiotherapy
combined with hyperthermia.
In one randomized prospective trial (RTOG 83-
05) high doses (4x8 Gy for 21 days) were
compared with conventional fractionation (20x2,5
Gy for 26 days) (Borgelt, 1980). There was no
significant difference in the response to irradiation
(60% vs 57%). This is the reason why tolerance to
healthy cells should be taken into consideration
during radiotherapy. Excessively high doses per
fraction are not recommended in the treatment of
tumours localised near the tissues with low
tolerancy, for example, in the nervous system or
parenchymatous organs.
According to Meder, high dose irradiation of
localised tumour (without metastases) can be
recommended in the case of:
al patients not suitable for surgery,
bl selective patients with melanoma of eyeballs,
ci postoperative irradiation to local and metastatic
tumours,
dl palliative irradiation for local reccurence,
metastases to Iymph nodes, single metastases to
skin, subcutaneous tissue and internal organs
(Meder, 1985).
THE AUTHORS' OWN RESULTS
In the period between January, 1, 1985 and
December, 31,1989,27 patients (14 men and 13
woman) with melanoma were irradiated
palliatively (aged 22-66) (Skowronek, 1997). Ali
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the patients were disqualified from repeated
surgery because of tumours inoperability. In all
cases, the c1inical diagnosis was confirmed on
pathological examination. Tumour localisation
was as follows: head and neck (7), chest and
abdomen (2), back (1), upper extremities (6),
lower extremities (11). Patients for irradiation were
qualitied in the case
of:
- local reccurence : 11 patients
- metastases to regional Iymph nodes : 16
patients.
They were irradiated with dose per fraction of
600 cGy, twice a week, to the total dose of 3600
cGy (18 patients) ar 4800 cGy (9 patients). The
dose of 4800 cGy was given in tumours greater in
diameter than 2-3 cm. 9 MV photons were used in
6, Co-60 beam in 15, and 10 MeV electrons in 6
of patients respectively. The energy was selected
depending on the localisation and the size of the
tumours. Between one and fourentry fields were
determined. After irradiation, the patients did not
receive any another therapy. The follow - up was
completed 31 December 1994.
In the group of 27 patients irradiated palliatively,
complete remission estimated 4 weeks after the
end of the irradiation was obtained in 14 patients,
incomplete in 8 and no remission in 5 patients
(table I).
Compiele Partial No remission
remission remission
local reccurence 7 1 3
Regionallymph
node metaslases 7 7 2
14(51,9%) 8(29,6%) 5(18,5%)
Table I Remission after radiotherapy for various tumours sites
For local recurrences, complete remission was
achieved in 63,6% of cases, partial remission in
9,1% and no remission in 27,3%. For metastases
to Iymph nodes complete remission occuredin
50,0% of cases, partial remission in 37,5%, and
no response to radiotherapy in 14,3%.
Eleven patients were still alive after 5 years
(40,7%), 9 of them (33,3%) without symptoms of
the disease. Two patients underwent surgery for
consecutive recurrences.
The correlations between the survival and time
of diagnosis when compared with choosen
prognostic factors, complete remission and
radiotherapy causes are shown in table II and III.
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Prognoslic tactors 5urvival rate n=
<5years n % > 5years n %
Age:
<47,2years 8 66,7 4 33,3 12
>47,2 years 8 53,3 7 46,7 15
Localisation ot
!he primaJY !esion:
Head and neek
6 85,7 1 14,3 7Chesl
Sack Upper limb 2 O 2
Lowerlimb 1 O 1
3 50,0 3 50,0 6
Upperlower 4 36,4 5 63,6 11
Complete
.remission:
Yes
No 4 28,6 10 71,4 14
12 92,3 1 7,7 13
16/27 59;3 11/27 40,7 27
Table II The 5 - year 5urvIVal rates and some selected
prognostic factors
mean survivallime (month)
Radiolherapy n= 5~year
survival
rale
fromthe fromlhe
dayof startof
diagnosis
radiotherapy
Local 11 8/11 63,0 44,5
recurrence (72,7%)
Regional 16 3116 35,2 20,4
Iymph (18,8%)
nade
metaslasis
27 11/27
/40,7%/
Table III The 5-year survival rates for various tumour sites
Among patients irradiated with the total dose of
3600 cGy 8 patients (44,4%), and 3 (33,3%)
irradiated with the .tocal dose of 4800 cGy
survived for 5 years.
A smali group of patients did not allow for any
statistical analysis.
In our own material, the patients were qualified
for radiotherapy in the case of local recurrence on
the site of the removed primary tumour or with
metastases to regional Iymph nodes. High doses
per fraction were applied twice a week in
accordance with the principles obtained in several
oncological centres (Adam, 1982; Habermalz,
1976; Hornsey, 1978; Katz, 1981). No remission
was observed only in5 patients out of 27.
Complete remission was seen in 14 patients
(46,7%), more often in the cases of local
reccurences (63,6%) than in the cases of
metastases to Iymph nodes (50,0%).
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The tendency to differentiate the 5-year survival
period was observed in patients irradiated for local
reccurence (72,7%), metastases to regional
Iymph nodes (21,3%) and also in the cases where
complete remission was achieved (71,4%) and in
progressive disease (28,6%).
The 5-year long survival for 11 patients
disqualified from surgery and irradiated
palliatively, in spite of the smali number of patients
in the group, may point to the usefullness of
radiotherapy with high doses per fraction for
patients with local reccurence after surgery or
metastases to regionallymph nodes.
CONLUSIONS
Nowadays there are no indications to recognise
melanoma as a radioresistant tumour. In spite of
the developments in radiobiology, there are still a
lot of aspects to investigate. The cause for the
different radiosensivity of melanoma cells for
different doses is probably connected with their
heterogeneity. The use of radiosensivity tests,
such as the indirect Survival Fraction Test (SF-2),
micronuclear test, a fibroblasts differentiation test,
may tacilitate the individualisation of the dose per
fraction protoco!.
Radiotherapy is still a method of choice in
palliative treatment for inoperable cases, for
patients not giving consent to an operation, ar for
the conservation of limbs. Better therapeutic
results will probably be obtained in the future by a
combined treatment (radio-, chemio-,
immunotherapy and hyperthermia) and by the
introduction of irradiation with a high ratio ot LPl=
(Rate, 1988).
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